NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

虛擬臨床試驗:專題調查

Virtual Clinical Trials - Thematic Research

出版商 GlobalData 商品編碼 1023534
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
虛擬臨床試驗:專題調查 Virtual Clinical Trials - Thematic Research
出版日期: 2021年08月05日內容資訊: 英文 84 Pages
簡介

傳統的臨床試驗模型已經過時,給患者、臨床試驗機構和申辦者帶來了許多問題。這些問題主要與患者招募和保留率低有關,導致臨床試驗延遲和成本高。虛擬臨床試驗利用數字技術和其他遠程服務來改善患者體驗和滿意度,同時拉近研究與患者的距離,為這些問題提供創新的解決方案。

即使在 COVID-19 大流行之前,使用虛擬組件的臨床試驗也在增加。 COVID-19 的封鎖和社交距離措施給臨床試驗造成了極大的混亂,並加速了虛擬臨床試驗的使用。之前沒有考慮過這種模式的公司,只能迅速引進新技術和新流程來維持業務的連續性,而且很多公司在疫情過後還會繼續使用虛擬臨床試驗,我能想到。

在過去的一年半里,許多主要的臨床研究組織 (CRO) 和電子臨床軟件提供商都擴展了自己的能力,以滿足對這些服務不斷增長的需求。近年來,出現了幾家專門從事虛擬臨床試驗的公司,並在大流行期間受到了極大的關注。

本報告調查了虛擬臨床試驗,包括有關醫療保健和技術、監管趨勢、COVID-19 對臨床試驗的影響、行業分析、競爭條件、領先公司等方面的信息......

目錄

目錄

  • 執行摘要
  • 市場公司
  • 專題簡報
  • 趨勢
  • 醫療保健趨勢
  • 技術趨勢
  • 監管趨勢
  • 宏觀經濟趨勢
  • 價值鏈
  • 同意說明文件電子版
  • 電子臨床結果評估
  • 遠程醫療
  • 家庭護理
  • 直接供應給患者
  • 行業分析
  • COVID-19 對臨床試驗的影響
  • 虛擬臨床試驗分析
  • 虛擬試驗對試驗率的影響
  • 關於採用虛擬考試的調查數據
  • 交易分析
  • 併購
  • 戰略聯盟
  • 融資交易
  • 工作分析
  • 案例研究
  • 第一個虛擬試驗,輝瑞的遙控器,由於發生率低而結束。
  • 為專業供應商 Science 37 開發虛擬試用空間
  • PPD 與專家合作,成為大流行期間虛擬臨床試驗的領先提供商
  • LEO 創新實驗室宣佈 Studies & Me 成為專注於皮膚病學的虛擬 CRO
  • 強生在 Heartline 和 CHIEF-HF 臨床試驗中實現了虛擬心臟病
  • 時間軸
  • 醫療保健行業調查
  • 社交媒體影響者
  • 公司
  • 上市公司
  • 私人公司

附錄

  • 縮寫
  • 參考文獻
  • 相關報導
  • 參考文獻
  • 關於作者
  • 我們的主題研究方法
  • 關於全球數據
  • 聯繫我們

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCHT285

The traditional trial model is outdated and causes multiple issues for patients, trial sites, and sponsors. These issues are predominantly related to low patient recruitment and retention rates, leading to trial delays and high costs. Virtual trials offer an innovative solution to these problems by improving patient experiences and satisfaction with the use of digital technologies and other remote services, as well as bringing the research closer to the patient.

An increasing number of trials were using virtual components before the COVID-19 pandemic. COVID-19 lockdowns and social distancing measures caused significant disruption to clinical trials and accelerated the use of virtual trials. Companies that had not considered this model before had no option but to rapidly implement new technologies and procedures to maintain business continuity. Research shows that many companies will continue to use virtual trials after the pandemic. Over the past 18 months, many leading clinical research organizations (CROs) and eClinical software providers have expanded their capabilities in response to the growing demand for these services. Several specialist virtual trial providers have also emerged in recent years and attracted considerable attention during the pandemic.

Scope

  • Key players in the virtual trial space: These include specialist virtual trial providers, CROs, eClinical solution providers, technology companies, contract development and manufacturing organizations (CDMOs), logistics companies, and in-home care providers.
  • Thematic briefing including a definition of virtual trials and the different technologies and processes used, such as eConsent, eCOA, telemedicine, direct-to-patient supply, and in-home care, as well as a review of the benefits and challenges to implementing these types of studies.
  • Key trends impacting the virtual trial space. Industry trends include the impact of COVID-19 on clinical trials and digital transformation in pharma, rise of the virtual trials specialists and the evolution of CROs, positive impact of virtual trials on accrual rates, and increased focus on patient centricity in trials. Technology trends include the role of wearable technology, mHealth, telemedicine, cloud, 5G, blockchain, cybersecurity, and artificial intelligence. Regulatory trends include the lack of regulatory frameworks for virtual trials, guidelines issues during COVID-19 to support continuation of clinical research, and the role of non-profit organizations such as the DTRA and CTTI in guiding companies to implement virtual trials. Macroeconomic trends including the increase seen in deals and jobs related to virtual trials since COVID-19.
  • Value chain looking at certain aspects of virtual trials, including eConsent, eCOA, telemedicine, direct-to-patient supply, and in-home care.
  • Industry analysis with a detailed analysis of virtual trials deals from the Clinical Trials database, as well comprehensive deals, jobs, and Influencer analyses. This section also includes case studies and survey and poll data.
  • Profiles of private and public companies in the virtual trials space.

Reasons to Buy

  • See who the leading players are in the virtual trials space by company type
  • See how the competitive landscape is evolving, with a review of company activity including mergers and acquisitions (M&A), strategic partnerships and funding deals, as well as a jobs analysis.
  • See what trends are driving the use of virtual trials, and also what challenges are impeding their uptake
  • See which technologies and processes are being used to bring research closer to patients.
  • Get a deep dive into clinical trial data, including the impact of COVID-19 on trials, the use of virtual components in trials over the past decade, and how virtual trials have improved trial accrual rates.

Table of Contents

Table of Contents

  • Executive Summary
  • Players
  • Thematic Briefing
  • Trends
  • Healthcare Trends
  • Technology Trends
  • Regulatory trends
  • Macroeconomic Trends
  • Value Chain
  • eConsent
  • Electronic Clinical Outcome Assessment
  • Telemedicine
  • In-Home Care
  • Direct-to-Patient Supply
  • Industry Analysis
  • The Impact of COVID-19 on Clinical Trials
  • Virtual Clinical Trials Analysis
  • Impact of Virtual Trials on Trial Accrual Rates
  • Survey Data on the Adoption of Virtual Trials
  • Deals Analysis
  • Mergers and Acquisitions
  • Strategic Partnerships
  • Funding Deals
  • Jobs Analysis
  • Case Studies
  • The First Virtual Trial, Pfizer's REMOTE, Was Terminated Due to Low Accrual Rates
  • Specialist Vendor Science 37 Is Pioneering the Virtual Trials Space
  • PPD Has Partnered with Specialists to Become a Leading Provider of Virtual Trials During the Pandemic
  • LEO Innovation Lab Spin-Off Studies&Me Launches as a Virtual CRO With a Focus in Dermatology
  • J&J Goes Virtual in Cardiology with its Heartline and CHIEF-HF Trials
  • Timeline
  • Healthcare Industry Polls
  • Social Media Influencers
  • Companies
  • Public Companies
  • Private Companies

Appendix

  • Abbreviations
  • Further Reading
  • Related Reports
  • Bibliography
  • About the Authors
  • Our Thematic Research Methodology
  • About GlobalData
  • Contact Us

List of Tables

List of Tables

  • Table 1: Healthcare Trends in the Virtual Trials Space
  • Table 2: Technology Trends in the Virtual Trials Space
  • Table 3: Regulatory Trends in the Virtual Trials Space
  • Table 4: Macroeconomic Trends in the Virtual Trials Space
  • Table 5: Examples of Virtual Trials by Pharmaceutical Companies
  • Table 6: M&As in the Virtual Trials Space, 2018-2021
  • Table 7: Examples of Strategic Partnerships in the Virtual Trials Space
  • Table 8: Examples of Funding Deals in the Virtual Trials Space
  • Table 9: Examples of Public Companies in the Virtual Trials Space
  • Table 10: Examples of Private Companies in the Virtual Trials Space

List of Figures

List of Figures

  • Figure 1: Who Are the Leading Players in the Virtual Trials Space?
  • Figure 2: Benefits of Virtual Trials
  • Figure 3: Challenges of Virtual Trials
  • Figure 4: Virtual Clinical Trials Value Chain
  • Figure 5: Examples of Virtual Trial Components Provided by Different Provider Types
  • Figure 6: Examples of eConsent Providers
  • Figure 7: Examples of eCOA Providers
  • Figure 8: Examples of Providers with Telemedicine Capabilities
  • Figure 9: Examples of In-Home Care Providers
  • Figure 10: Examples of Direct-to-Patient Supply Providers
  • Figure 11: Ongoing Disruption of Clinical Trial Activity Due to COVID-19
  • Figure 12: COVID-19 Will Continue to Impact Drug Development Activities in 2021
  • Figure 13: The Proportion of Trials Utilizing Virtual or Digital Components Has Increased Steadily Since 2004
  • Figure 14: eDiary Is the Most Common Type of Virtual or Digital Component Used in Trials
  • Figure 15: Metabolic Disorders Is the Leading Therapy Area for Trials Utilizing Virtual or Digital Components
  • Figure 16: Breakdown of Trials by Phase and Geography
  • Figure 17: Top 20 Sponsors of Trials with Virtual or Digital Components
  • Figure 18: Reasons for Clinical Trial Suspension or Termination, 2011-2021
  • Figure 19: Proportion of Trials Impacted by Low Accrual Has Decreased Over the Past 10 Years
  • Figure 20: Trials for Rare Cancers are Most Impacted by Low Accrual Rates
  • Figure 21: Clinical Trial Disruption Was a Primary Business Concern for the Industry in June 2020
  • Figure 22: Addressing Clinical Trial Disruptions Related to the COVID-19 Outbreak
  • Figure 23: COVID-19 Accelerated Use of Virtual Trials
  • Figure 24: Respondents Expect Virtual Trials to Be Used Frequently Within 1-2 Years
  • Figure 25: The Number of Deals in the Virtual Trials Space Has Increased Over the Past 12 Months
  • Figure 26: Partnerships Involving Specialist Virtual Trial Vendors, Most Common Since 2018
  • Figure 27: Specialist Virtual Trial Vendors Have Received the Most VC Funding Since 2018
  • Figure 28: Numbers of Posted Jobs Related to Virtual Trials Has Increased Since 2019
  • Figure 29: Jobs Related to eClinical Technologies Are More Common
  • Figure 30: Jobs That Mention Virtual or Decentralized Trials Have Increased Since Q1 2020
  • Figure 31: Virtual Trial Jobs by Geography
  • Figure 32: Top 20 Companies Posting Jobs Relating to Virtual Trials, 2019-2021
  • Figure 33: The Apple Heartline Mobile Application
  • Figure 34: The Virtual Trials Timeline
  • Figure 35: Therapy Areas Most Suitable for Use of Digital Health Technologies in Clinical Trials
  • Figure 36: Digital Measures with the Most Potential for Immediate Use in Clinical Trials
  • Figure 37: Main Benefits of Using Digital Health Technologies in Clinical Trials
  • Figure 38: Main Barriers to Using Digital Technologies in Clinical Trials
  • Figure 39: Impact of Digital Health Technologies in Clinical Trials Over the Next Five Years
  • Figure 40: Clinical Trial Trends in GlobalData's Digital Pharma Influencer Database, January 2020 to April 2021
  • Figure 41: Examples of Top Posts Related to Virtual Trials, 2020-2021
  • Figure 42: Our Five-Step Approach for Generating a Sector Scorecard